<unk>  (or<unk>  refers to the combination of aspirin and a P2Y12 receptor antagonist.<unk>  is approved for SIHD and interventions for ACS, such as stent placement following PCI or CABG. The duration of treatment with<unk>  for each of these categories differs and guidelines for treatment have been updated in the 2016 ACC/AHA Guideline Focused Update on Duration of<unk>  in Patients With Coronary Artery Disease. Much of the studies done on<unk>  compared the use of different types of P2Y12 receptor antagonists, the dosage of drugs, as well as the duration of treatment. While the use of<unk>  is associated with decreased risk of stent thrombosis, the benefits of treatment should be weighed against the increased risk of major bleeding.
Dual antiplatelet therapy
Carotid stenting
Intracoronary pharmacotherapy
Thrombectomy
Pulmonary thromboendarterectomy
Low molecular weight heparin
Warfarin administration and monitoring
Inferior vena cava filter